Samsung Biologics invests in new plant to expand Bio Campus
Samsung Biologics, the leading end-to-end CDMO, is set to start building a new plant based in North Korea, to expand its biomanufacturing capabilties.
Samsung Biologics, the leading biotech CDMO, has announced that they will be opening a fifth biomanufacturing plant, not far from their existing Songdo site. The expansion comes in response to increased market demand for biopharmaceuticals.
The building of the 96,000 m2 plant is set to commence this year, with a view to be operational come 2025. It will be the first facility to run under their Bio Campus initiative. The plant will have a capacity of 180,000 litres, bringing Samsung Biologic’s global biomanufacturing capacity to 784,000 litres.
“Given the continuing increase in the demand for outsourced manufacturing of biopharmaceuticals, we are proactively making this investment in alignment with our growth strategy to further strengthen our standing as a leading CDMO,” stated John Rim, President and CEO of Samsung Biologics. “The new facility will enable us to provide our customers with even greater innovation and services that will increase speed to market and flexibility.”
Samsung Biologics are expecting the plant to increase their operational output and efficiency by building on their already acquired expertise, and the technology they have honed through the years in their previous plants. This plant will take this experience one step further with increased use of digitalised technologies and the inclusion of important sustainability-led features.
The second Bio Campus, on which the plant will be based, will also be home to further operational plants and an innovation hub. The campus will cover 360,000 m2 of land and will bear the fruits of a KRW 7.5 trillion investment.
The company’s existing plants are nearly fully functional, with the latest, plant 4, due to be fully operational by the middle of this year.
To further streamline their operations and support their expansion into the US, Samsung Biologics are opening an office in New Jersey, USA in April.
“Our increased US presence will allow us to provide support for clients with even greater agility and engage the broader biotech industry more than ever,” commented Rim.
Related News
-
News On Track at Pharmapack 2024 - The Track Sponsor interview: BD Pharmaceuticals
January 2024 brings both a new year and Europe’s leading packaging and drug delivery event. Bringing the world’s experts in pharmaceutical packaging together in Paris, France, Pharmapack 2024 brings exciting opportunities to learn and colla... -
News Patients vs Pharma – who will the Inflation Reduction Act affect the most?
The Inflation Reduction Act brought in by the Biden administration in 2022 aims to give better and more equitable access to healthcare in the USA. However, pharma companies are now concerned about the other potential costs of such legislation. -
News Roche breaks into the obesity drug market with the acquisition of Carmot Therapeutics
In a bid to diversify their therapeutic offerings, Roche takes over Carmot Therapeutics in $2.7 billion deal, with one obesity drug spearheading the venture into the field as they prep for a Phase II in-human trial. -
News Biden backs Cold-War measures to shore-up medical supply chains
In a recent strategy to combat rising inflation and the cost of living crisis, President Joe Biden has invoked a Cold War-era act to increase investment in a selection of medicines and supplies. -
News Women in Pharma: Delivering solutions for gender diversity
In our new monthly series, we interview women from across the pharmaceutical industry and supply chain to discuss the importance of gender diversity in healthcare, the workplace, and beyond. -
News CPHI Barcelona Speaker Interview – What the US FDA’s Quality Management Maturity Means for the Pharma Industry
At CPHI Barcelona (24–26 October, 2023), we spoke to Sireesha Yadlapalli, CEO of Pharmatech Associates, who gave a presentation on the implications of the US FDA’s Quality Management Maturity (QMM) Initiative, and spoke on the panel of the ... -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News Wegovy and weight-loss drugs driving demand for manufacturers that can fill syringes
Injectable weight-loss treatments are prompting contract manufacturers to invest and include fill-finish services into their service portfolios, in a bid to attract pharmaceutical giants developing drugs similar to Novo Nordisk's Wegovy.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance